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Abstract
It has previously been found that combination therapy with anti-CTLA-4 and anti-4-1BB antibodies may enhance tumor
immunity. However, this treatment is not efficient against all tumors, and it has been suggested that variations in tumor
control may reflect differences in the immunogenicity of different tumors. In the present report, we have formally tested this
hypothesis. Comparing the efficiency of combination antibody therapy against two antigenically distinct variants of the
B16.F10 melanoma cell line, we observed that antibody therapy delayed the growth of a variant expressing an exogenous
antigen (P,0.0001), while this treatment failed to protect against the non-transfected parental line (P= 0.1850) consistent
with published observations. As both cell lines are poorly immunogenic in wild type mice, these observations suggested
that the magnitude of the tumor targeting T-cell repertoire plays a major role in deciding the efficiency of this antibody
treatment. To directly test this assumption, we made use of mice expressing the exogenous antigen as a self-antigen and
therefore carrying a severely purged T-cell repertoire directed against the major tumor antigen. Notably, combination
therapy completely failed to inhibit tumor growth in the latter mice (P= 0.8584). These results underscore the importance of
a functionally intact T-cell population as a precondition for the efficiency of treatment with immunomodulatory antibodies.
Clinically, the implication is that this type of antibody therapy should be attempted as an early form of tumor-specific
immunotherapy before extensive exhaustion of the tumor-specific T-cell repertoire has occurred.
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Introduction
Following the overwhelming success of immunomodulatory
antibodies in the treatment of autoimmune diseases, it is now time
to fully exploit the potential of this class of potent drugs in the
treatment of cancer. Several antibodies are already in clinical use,
while others are under investigation in pre-clinical studies [1–3]. In
this regard, antibodies against co-stimulatory molecules, such as
cytotoxic T lymphocyte antigen 4 (CTLA-4) and 4-1BB, have
emerged as potentially important therapeutics against various
tumors [4,5].
CTLA-4 is a co-inhibitory receptor expressed on T-cells shortly
after their activation [6], and it has been found to play an
important role in the modulation of antigen-specific immune
responses. In addition, expression of CTLA-4 is critical to the
functionality of regulatory T-cells (Tregs) in vivo [7]. Collectively,
blocking of this molecule allows for efficient stimulation of immune
responses towards weak antigens, such as tumor antigens;
however, it also increases the risk of self-reactivity, and studies in
murine models have underscored this risk. Perhaps more
importantly, autoimmune manifestations have also been observed
in human patients [8], and careful clinical management is
essential, if immune-related toxicities are to be kept acceptable [9].
4-1BB is a molecule belonging to the tumor necrosis superfam-
ily. It is transiently up-regulated on T-cells subsequent to
activation, and ligand binding is known to augment CD8 T-cell
activity [10,11]. In various tumor models, agonistic anti-4-1BB
antibodies have been found to improve tumor control [10].
Interestingly, even though 4-1BB signaling may render effector T-
cells resistant to the inhibitory effect of Tregs [12], treatment with
anti-4-1BB antibodies has also been found to reduce autoimmu-
nity in lupus-prone mice [13].
Since agonistic anti-4-1BB antibodies appear to both improve
anti-tumor responses and, in some cases, reduce autoimmunity, it
has been suggested to combine this treatment with antibodies
blocking CTLA-4 [4,5]. In fact, a study published by Kocak et al.
seems to provide proof-of-concept in this respect [5]. Thus, these
authors examined the efficacy of this combinatorial regimen in two
distinct tumor models; MC38 colon carcinoma cells and B16
melanomas. Interestingly, they found that only MC38 challenged
mice were significantly protected. As a plausible explanation for
this, it was suggested that the difference in clinical effect might
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result from differences in the intrinsic immunogenicity of the tested
tumor cell lines. Yet, as only two very different tumor cell lines
were studied, this explanation together with its implications could
not be scientifically verified. Considering the clinical importance of
Figure 1. Treatment with agonistic anti-4-1BB and blocking anti-CTLA-4 delays tumor growth only in mice challenged with tumor
cells expressing a strong foreign antigen. Mice (n = 8–10 mice/group) were inoculated s.c. in the right flank with 106 melanoma cells at day 0
and antibodies were administered i.p. as described. A: a) Mice vaccinated with 26107 IFU Ad-IiGP in the right hind footpad 5 days post B16.F10
inoculation (pt). b) As in a, plus treatment with 200 mg anti-4-1BB at days 9 and 12 pt. c) As in a, plus treatment with 100 mg anti-CTLA-4 at day 5 and
50 mg anti-CTLA-4 at days 7 and 9 pt. d) As in a, plus treatment with anti-4-1BB and anti-CTLA-4 as in b and c, respectively. e) B16.F10 tumor cells, no
vaccination, antibody treatment as in d. f) B16.F10 tumor cells, no treatment. P-values: e vs. f ,0.0001; a vs. d = 0.0220; d vs. e = 0.9400. B: Solid lines
indicate mice challenged with B16.F10-GP cells; dashed lines indicate mice challenged with B16.F10 cells. Grey lines indicate mice that did not receive
any treatment. Black lines indicate mice treated i.p. with 200 mg anti-4-1BB at days 9 and 12 plus 100 mg anti-CTLA-4 at days 5 and 50 mg anti-CTLA-4
at days 7 and 9 pt. Mortality of tumor bearing mice as a function of time. P-values: a vs. b,0.0001; a vs. d = 1.0000; b vs. d = 0.0003; c vs. d = 0.1850 C:
Tumor volumes as a function of time; data are presented as mean 6 SEM. P-values: a vs. b ,0.0001.
doi:10.1371/journal.pone.0066081.g001
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developing new combinational treatments of human cancers, we
decided to revisit the above subject and formally test whether the
anti-tumor potential of combining these antibodies is in fact
limited by the intrinsic immunogenicity of the involved tumor cells
or whether it is more the availability of a functionally intact,
tumor-specific T-cell repertoire, which is critical.
Accordingly, we made use of two closely related cell lines: wild
type (WT) B16.F10 cells and a gene modified variant, B16.F10-
GP, expressing the immunodominant epitope of the glycoprotein
(GP) of lymphocytic choriomeningitis virus (LCMV) [14,15]. WT
B16.F10 cells are poorly immunogenic, in part, due to weak MHC
class I expression and a nonexistent MHC class II expression [16].
In contrast, B16 variants expressing exogenous transgenes are
quite antigenic despite poor intrinsic immunogenicity, and for this
reason they are commonly used to monitor the efficiency of
otherwise, e.g. vaccine, induced anti-tumor immune responses
[4,14,17].
As an additional tool, we employed a mouse strain (Alb-1)
expressing LCMV-GP as a self-antigen under the albumin
promoter [18]. In these mice, the GP-specific CD8 T-cell
repertoire is severely depleted, and, as a consequence, GP-specific
responses in Alb-1 mice are greatly reduced compared to those
induced in their WT counterparts [18].
Using the described experimental approach, we find that
differences in the protective capacity of combinatorial therapy
with antagonistic anti-CTLA-4 and agonistic anti-4-1BB antibod-
ies do not so much reflect differences in the intrinsic immunoge-
nicity of the tumor cells as the availability of a functionally intact
T-cell repertoire targeting antigens expressed by the tumor cells.
Materials and Methods
Ethics Statement
Experiments were conducted in accordance with national
Danish guidelines (Amendment #1306 of November 23, 2007)
regarding animal experiments as approved by the Danish Animal
Inspectorate, Ministry of Justice, permission #2011/561–87.
Mice
Alb-1-GP transgenic C57BL/6 mice were the progeny of
breeding pairs originating from the animal facility of Spital, Zu¨rich
[18], and kindly provided by Daniel Pinschewer. WT C57BL/6
mice were purchased from Taconic M&B (Ry, Denmark).
Tumor Cell Lines
B16.F10 and B16.F10-GP (expressing the minimal epitope of
the LCMV glycoprotein, GP33-41) melanoma cells were cultured
Figure 2. Combined antibody therapy with agonistic anti-4-1BB and anti-CTLA-4 antibodies does not delay growth of B16.F10-GP
tumors in GP tolerant Alb-1 mice. Mice (n = 10-11 mice/group) were inoculated s.c. in the right flank with 106 B16.F10-GP melanoma cells at day
0. Grey lines indicate mice that did not receive any treatment. Black lines indicate mice treated i.p. with 200 mg anti-4-1BB at day 9 and 12 plus 100 mg
anti-CTLA-4 at day 5 and 50 mg anti-CTLA-4 at day 7 and 9 pt. A) Mortality of tumor bearing mice as a function of time. P-values: a vs. b = 0.8740 B)
Tumor volumes as a function of time; data are presented as mean 6 SEM. P-values: a vs. b = 0.9992.
doi:10.1371/journal.pone.0066081.g002
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in DMEM 1965 supplemented with 10% FCS, glutamine,
streptomycin, and penicillin. Additionally, B16.F10-GP cells were
grown in the presence of G418 (0.8 mg/ml). Both cell lines were
kind gifts from Hanspeter Pircher, Germany [14].
Antibodies
Agonistic anti-4-1BB stimulating monoclonal antibody (mAb)
from 3H3 hybridomas [11] and anti-CTLA-4 mAb from 9H10
hybridomas [19] were purified from cell culture supernatant using
a protein G column.
Adenoviral Vector
Replication deficient E1-deleted Ad5 vector with a non-
functional E3 gene expressing GP of LCMV linked to the murine
invariant chain (Ii), designated Ad5-IiGP, was produced as
described previously [20].
Injections and Tumor Measurements
All mice were subcutaneously injected with 106 melanoma cells
in the right flank at day 0. The mice were shaved at the injection
site prior to inoculation. When the tumors reached the size of
$12 mm, the mice were euthanized for ethical reasons. The
tumor volumes were calculated as length6width260.5236. When
relevant, vaccinations with human Ad 5-based vectors were
administered in the right hind footpad 5 days post tumor
inoculation.
Statistical Analysis
Comparison among groups in the survival experiments was
analyzed by the log-rank test (Mantel-Cox). Tumor volume are
presented as mean 6 s.d. and analyzed by 2way ANOVA. Prism
6, GraphPad software (GraphPad Software Inc.) was used for all
statistical analysis. P,0.05 was considered statistically significant.
Results and Discussion
Treatment with Agonistic Anti-4-1BB and Blocking Anti-
CTLA-4 Antibodies Augments Tumor Control
We have previously shown that the growth of B16.F10-GP
tumors can be partially controlled by therapeutic vaccination with
Ad5 vectors expressing GP [17]. We could also demonstrate that
tumor control was markedly improved if GP was tethered to the
MHC class II associated invariant chain (Ii). However, under the
conditions we normally used, we very rarely observed any long-
term survivors, and for this reason we have been searching for
treatment modalities, which in combination with our vaccine
would result in improved long-term tumor control. Different
immunomodulatory antibodies have been tested with varying
success [21]. In the context of these studies, we decided to test a
combination of agonistic anti-4-1BB with blocking anti-CTLA-4.
This regimen has been described by Kocak et al. to both enhance
cancer therapy and reduce autoimmunity in a murine carcinoma
model [5]. Interestingly, the antibody treatment they used failed to
protect B16.F10 challenged mice. Nevertheless, we hypothesized
that by also targeting B16.F10 melanomas through antigen-
specific vaccination, a clinically relevant improvement would be
observed.
When mice were challenged with B16.F10-GP, followed by
antigen-specific vaccination and immune modulatory antibody
treatment, we observed significantly improved tumor control
compared to mice given no antibody treatment (P= 0.0220–
Figure 1A). Hence, at first sight, the antibody treatment seemed to
significantly increase the protective potential associated with
antigen-specific vaccination. However, to our surprise unvacci-
nated mice, which only received the antibody treatment were
equally well protected (P= 0.9400), indicating that the antibody
treatment sufficed for a marked clinical effect.
Gene Modified B16.F10 Cells are much more Susceptible
to Antibody-induced Tumor Control than their WT
Counterparts
As our results seemingly conflicted with those of Kocak et al.
[5], describing that this antibody combination was insufficient for
treatment B16 tumors, we hypothesized that the success of this
antibody treatment relates to the presence of a ‘‘strong’’ foreign
antigen on the tumor cells combined with a substantial population
of matching T-cells. This would not be the case for WT tumor
cells, which would not be expected to express any strong antigens.
To test this prediction, we injected WT mice with 106 B16.F10
cells, with or without expression of exogenous antigen (GP),
followed by antibody treatment. The results presented in
Figure 1B–C clearly support our hypothesis: antibody treatment
did not significantly impact tumor growth in B16.F10 challenged
mice (P= 0.1850); whereas the effect on B16.F10-GP challenged
mice were highly significant (P,0.0001). Untreated mice were
equally susceptible to both cell lines (P= 1.000).
The Antibody-induced Control of B16.F10-GP Cells is
Abolished in Mice Carrying GP as a Self-antigen
The observed difference in the efficiency of antibody therapy
against tumor cells bearing exogenous antigen versus no antigen
underscored a role for functionally intact, tumor-specific T-cells in
the antibody induced tumor control. Although overall T-cell
depletion of course would validate a role of T-cells, this treatment
would not provide any information regarding the fine specificity
requirements of the involved cells. For this reason, we decided to
use a subtler approach to test whether successful antibody induced
tumor control requires a functionally intact population of tumor-
specific CD8 T-cells. Thus, we used Alb-1 mice, which express GP
as a self-antigen and for that reason have a severely depleted T-cell
repertoire for this antigen compared to WT mice [18].
As predicted, if an intact tumor targeting T-cell population play
a decisive role when it comes to the efficiency of this antibody
combination, Alb-1 mice, unlike WT mice, were equally
susceptible to tumor challenge with B16.F10-GP cells whether
they received antibody therapy or not (P= 0,8584 – Figure 2).
Concluding Remarks
The results of the present study confirm that this antibody
combination is inefficient against the WT B16 cell line. In contrast,
the antibodies could efficiently delay the growth of a variant of this
tumor cell line expressing a foreign antigen. Since the two cell lines
are identical except for the presence of the transgene, and there is
clear evidence in the literature that neither of these cell lines are
very immunogenic when inoculated into normal WT mice [15],
our results strongly indicate, that availability of tumor-targeting T-
cell repertoire represents a key factor in deciding the clinical
efficiency of combination therapy with anti-4-1BB and anti-
CTLA-4. Furthermore, the efficiency of antibody treatment
clearly relates to the size of the T-cell repertoire targeting antigens
expressed by the tumor cells. Thus, in mice (Alb-1) with a T-cell
repertoire purged of most T-cells specific for the major tumor
antigen relevant under the current test conditions (GP) [18],
combined antibody treatment did not significantly delay the
growth of GP-expressing tumor cells. Some might argue that it is
self evident that the presence of tumor-targeting T-cells represents
Tumorspecific T-Cells in Combined Antibody Therapy
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a precondition for immunmodulatory antibodies like anti-CTLA-4
and anti-4-1-BB to have an effect on tumor growth. However, this
insight is often ignored or forgotten in actual clinical practice.
Thus, since cancer immunoediting is assumed to rapidly remove
the most immunogenic cancer cells [22], the present findings serve
to underscore that this antibody combination therapy is likely to be
efficient only in cases where the remaining low-immunogenic
tumor cells express tumor antigens for which there is little or no
purging of the naı¨ve T-cell repertoire, i.e. neoantigens represent-
ing mutated self or viral antigen. Furthermore, as prolonged
cancer growth is believed to be associated with functional
impairment of relevant T-cells [23,24], results like ours tend to
imply that immunomodulatory antibody treatment should be
tested as an early treatment modality – before T–cell exhaustion is
severely progressed - and not as a last resort.
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